GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Berry Genomics Co 000710.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.61

+0.84%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥929.8m

FY2016FY2025

Net income

−CN¥196.8m

FY2016FY2025

Free cash flow

−CN¥5.1m

FY2016FY2025

Shareholders' equity

CN¥1.48bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥929.8mCN¥1.08bnCN¥1.15bnCN¥1.37bnCN¥1.42bnCN¥1.54bnCN¥1.62bnCN¥1.44bnCN¥1.17bnCN¥921.7m
Gross profitCN¥401.2mCN¥474.4mCN¥483.2mCN¥546.2mCN¥594.4mCN¥779.4mCN¥964.1mCN¥819.8mCN¥700.3mCN¥564.7m
Research and developmentCN¥104.4mCN¥95.4mCN¥110.0mCN¥106.7mCN¥128.2mCN¥125.8mCN¥119.5mCN¥91.3mCN¥33.6mCN¥48.6m
Operating income−CN¥71.2m−CN¥160.6m−CN¥436.8m−CN¥280.0m−CN¥98.8mCN¥258.7mCN¥450.2mCN¥305.1mCN¥275.1mCN¥182.4m
Net income−CN¥196.8m−CN¥192.4m−CN¥427.2m−CN¥248.9m−CN¥110.8mCN¥210.7mCN¥390.6mCN¥268.1mCN¥232.7mCN¥151.0m
Diluted earnings per share-0.56-0.54-1.22-1.48-0.300.561.100.7814.230.74

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥2.28bnCN¥2.38bnCN¥2.74bnCN¥3.20bnCN¥3.52bnCN¥3.24bnCN¥3.07bnCN¥2.18bnCN¥1.81bnCN¥548.0m
Cash and short-term investments—CN¥400.1mCN¥352.0mCN¥338.1mCN¥421.7mCN¥633.1mCN¥417.9mCN¥423.6mCN¥411.6mCN¥74.0m
Total liabilitiesCN¥780.1mCN¥669.6mCN¥846.6mCN¥871.5mCN¥996.0mCN¥821.5mCN¥721.8mCN¥235.7mCN¥245.9mCN¥434.0m
Debt—CN¥156.7mCN¥248.3mCN¥348.2mCN¥399.3mCN¥359.8mCN¥256.1m—CN¥29.3mCN¥107.6m
Shareholders' equityCN¥1.48bnCN¥1.68bnCN¥1.86bnCN¥2.30bnCN¥2.49bnCN¥2.39bnCN¥2.33bnCN¥1.90bnCN¥1.54bnCN¥114.1m
Shares outstanding354m354m350m169m366m373m357m342m16m203m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥70.6mCN¥88.0mCN¥111.0mCN¥21.2mCN¥94.0mCN¥161.3mCN¥123.1mCN¥165.3mCN¥74.4m−CN¥14.2m
Capital spending−CN¥75.7m−CN¥56.8m−CN¥55.1m−CN¥73.3m−CN¥336.7m−CN¥112.5m−CN¥295.3m−CN¥165.9m−CN¥204.8m−CN¥57.9m
Free cash flow−CN¥5.1mCN¥31.2mCN¥55.9m−CN¥52.1m−CN¥242.7mCN¥48.8m−CN¥172.2m−CN¥529,680−CN¥130.5m−CN¥72.1m
Dividends paid−CN¥4.7m−CN¥8.7m−CN¥15.5m−CN¥28.3m−CN¥20.3m−CN¥29.2m−CN¥8.4m−CN¥762,426−CN¥862,877−CN¥2.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥236.6mCN¥210.2mCN¥244.2mCN¥238.2mCN¥229.7mCN¥217.8mCN¥255.5mCN¥270.9m
Gross profitCN¥117.5mCN¥108.2mCN¥73.8mCN¥116.8mCN¥102.9mCN¥107.8mCN¥58.1mCN¥143.5m
Operating income−CN¥7.5m−CN¥4.9m−CN¥49.4m−CN¥23.6m−CN¥14.3m−CN¥2.3m−CN¥194.7mCN¥5.7m
Net income−CN¥24.2m−CN¥19.7m−CN¥144.3m−CN¥25.3m−CN¥20.8m−CN¥6.5m−CN¥202.8mCN¥1.1m
Diluted earnings per share-0.07-0.06-0.41-0.07-0.06-0.02-0.570.00
Cash from operations———−CN¥2.0mCN¥2.0m−CN¥34.0m—CN¥9.0m
Capital spending−CN¥12.0m−CN¥13.0m−CN¥12.0m−CN¥26.0m−CN¥24.0m−CN¥12.0m−CN¥21.0m−CN¥13.0m
Free cash flow———−CN¥28.0m−CN¥22.0m−CN¥46.0m—−CN¥4.0m
Total assetsCN¥2.16bnCN¥2.22bnCN¥2.28bnCN¥2.34bnCN¥2.42bnCN¥2.42bnCN¥2.38bnCN¥2.54bn
Cash and short-term investments———CN¥320.2mCN¥370.4mCN¥362.1mCN¥400.1mCN¥241.9m
DebtCN¥10.0m——CN¥156.3mCN¥162.6mCN¥125.1mCN¥113.4mCN¥107.0m
Shareholders' equityCN¥1.42bnCN¥1.45bnCN¥1.48bnCN¥1.62bnCN¥1.64bnCN¥1.67bnCN¥1.68bnCN¥1.87bn

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin43.1%44.0%42.0%39.9%41.8%50.6%—
Operating margin-19.3%-14.9%-37.9%-18.9%-6.9%17.0%—
Net margin-21.2%-17.8%-37.1%-18.2%-7.8%13.7%—
Return on equity-13.3%-11.5%-22.9%-10.8%-4.5%8.8%—
Return on assets-8.6%-8.1%-15.6%-7.8%-3.1%6.5%—
Free cash flow yield4.0%3.9%4.6%5.4%11.3%7.0%—
Revenue growth-13.8%-6.4%-15.8%-3.8%-7.7%-4.8%—
Earnings growth2.3%-55.0%71.6%124.6%-152.6%-46.1%—
Current ratio1.96x2.44x1.93x2.45x2.48x3.61x—
Debt to equity—0.07x0.13x0.14x0.15x0.15x0.11x
Equity ratio64.6%70.4%68.0%71.9%70.7%73.6%—
Interest coverage-18.00x-15.79x-26.28x-14.67x-4.58x16.16x—
R&D as a share of sales11.2%8.9%9.6%7.8%9.0%8.2%—
Buybacks as a share of market value0.2%-1.2%-107.9%54.0%1.8%-4.6%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-12.1%-9.6%7.6%
Operating income-36.7%——
Net income-7.5%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.6%42.1%43.8%50.4%
Operating margin-11.5%-21.0%-10.5%3.6%
Net margin-19.4%-23.5%-12.9%0.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-20.3-15.6-9.4-7.7-64.167.433.440.74.063.9
Price to sales4.32.83.51.45.09.28.17.60.810.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 25 May 2001.

FY2001
Paid in the year0.15
  • 1-to-1 reverse split · 1 Sept 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.